RNAi Technology

Global RNAi Technology Market to Reach US$7.0 Billion by 2030

The global market for RNAi Technology estimated at US$2.9 Billion in the year 2024, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. Drug Discovery & Development Application, one of the segments analyzed in the report, is expected to record a 18.8% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the Therapeutics Application segment is estimated at 12.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$767.6 Million While China is Forecast to Grow at 14.6% CAGR

The RNAi Technology market in the U.S. is estimated at US$767.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 14.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.9% and 13.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.1% CAGR.

Global “RNAi Technology” Market – Key Trends & Drivers Summarized

How Is RNAi Technology Redefining the Landscape of Precision Medicine?
RNA interference (RNAi) technology has rapidly emerged as a transformative tool in biomedical science, enabling highly specific gene silencing to modulate disease-related protein expression. By utilizing small interfering RNA (siRNA) and microRNA (miRNA) to inhibit mRNA translation, RNAi offers a mechanism to therapeutically target previously `undruggable` genes. Its precision in selectively shutting down aberrant gene expression has made it a cornerstone in next-generation therapeutic platforms, particularly for genetic disorders, cancers, and viral infections. The approval of RNAi-based drugs such as patisiran and givosiran by regulatory bodies like the FDA and EMA has validated the clinical potential of this modality. Growing interest in rare disease treatment is amplifying RNAi’s importance, as these conditions often arise from single-gene mutations. Furthermore, advances in lipid nanoparticle (LNP) and GalNAc-conjugated delivery systems have enhanced RNAi bioavailability and safety, enabling effective liver-targeted therapies. Pharmaceutical companies are increasing their RNAi R&D investments, supported by growing partnerships between biotech startups and big pharma. With ongoing success in clinical trials for conditions like hypercholesterolemia, amyloidosis, and hemophilia, RNAi is quickly expanding from experimental status to mainstream biopharmaceutical application.

What Are the Technological Bottlenecks and Innovations in RNAi Delivery?
The efficiency and specificity of RNAi therapy hinge critically on its delivery to target cells and tissues—a longstanding challenge in the field. Traditional delivery approaches faced degradation issues in the bloodstream and off-target effects, limiting clinical viability. However, the advent of LNPs, GalNAc conjugates, and polymer-based systems has revolutionized RNAi transport, allowing for organ-specific uptake and reduced immune activation. Liver-targeted delivery remains the most advanced, with GalNAc-siRNA conjugates showing significant promise in treating hepatic diseases. Researchers are now extending delivery capabilities to non-hepatic tissues, such as the central nervous system and lungs, using advanced carriers like dendrimers, exosomes, and aptamers. The integration of AI and machine learning in designing optimal siRNA sequences is also streamlining the discovery pipeline by predicting off-target risks and improving stability. In parallel, chemical modification strategies—such as 2`-O-methyl and phosphorothioate backbones—are enhancing siRNA half-life and cellular uptake. The miniaturization of high-throughput screening platforms and use of CRISPR-based analytics are accelerating validation of RNAi targets. While immunogenicity and scalability remain ongoing concerns, technological convergence is steadily dismantling these barriers, moving RNAi into broader clinical and commercial application.

Which Sectors Are Driving the Proliferation of RNAi Applications?
While healthcare remains the primary domain for RNAi deployment, its applications are growing across several other sectors. In human therapeutics, RNAi is being developed to treat a range of genetic, metabolic, and infectious diseases. Oncology is emerging as a significant field of interest, with efforts to silence genes involved in tumor growth, metastasis, and drug resistance. Agricultural biotechnology is leveraging RNAi for crop protection, using gene silencing to confer resistance against pests, viruses, and fungal pathogens without introducing foreign proteins. Animal health applications are also expanding, including RNAi-based vaccines and treatments for zoonotic diseases. RNAi is further being explored in antiviral defense, especially for RNA viruses such as SARS-CoV-2, influenza, and hepatitis B. Research organizations and universities are employing RNAi in functional genomics to decode gene function at scale. Environmental monitoring is another emerging niche, where RNAi is used to detect or control invasive species through species-specific gene targeting. These cross-sectoral applications are fueling market growth and spurring interdisciplinary collaborations. The need for novel, sustainable, and precision-targeted interventions across industries underscores the foundational importance of RNAi in future innovation.

The Growth in the RNAi Technology Market Is Driven by Several Factors...
The RNAi technology market is witnessing rapid growth driven by a unique mix of therapeutic demand, regulatory advancements, and platform scalability. The increasing burden of rare and chronic diseases, coupled with a need for highly targeted therapies, is creating strong clinical demand for RNAi-based solutions. The success of early RNAi therapeutics has generated regulatory confidence, expediting the approval process and attracting greater venture capital investment. Improvements in RNA chemistry and delivery systems are expanding the spectrum of treatable conditions, especially those involving hepatic, cardiovascular, and oncological pathways. Pharmaceutical companies are leveraging RNAi to complement or replace traditional small molecules in complex disease targets. Additionally, governments and public health bodies are investing in RNAi for pandemic preparedness and next-generation vaccine platforms. Agricultural and environmental use cases are gaining traction due to the need for pesticide alternatives and ecologically safe pest control. Academic partnerships and open-source genome libraries are facilitating rapid innovation in target discovery and validation. Moreover, advancements in AI for sequence optimization and delivery prediction are improving cost-efficiency and development speed. Collectively, these factors are positioning RNAi as a disruptive force across therapeutic, agricultural, and environmental biotech landscapes.

SCOPE OF STUDY:

The report analyzes the RNAi Technology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Application (Drug Discovery & Development, Therapeutics, Functional Genomics, Other Applications); End-User (Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

• Alnylam Pharmaceuticals
• Arbutus Biopharma Corporation
• Arcturus Therapeutics
• Arrowhead Pharmaceuticals
• AstraZeneca
• Benitec Biopharma
• Dicerna Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Ionis Pharmaceuticals
• Merck & Co., Inc.
• Moderna, Inc.
• Novartis AG
• OLIX Pharmaceuticals, Inc.
• Phio Pharmaceuticals Corp.
• ProQR Therapeutics
• Qiagen N.V.
• Quark Pharmaceuticals, Inc.
• Sanofi
• Silence Therapeutics PLC

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.